Your browser doesn't support javascript.
loading
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Enshaei, Amir; Joy, Melvin; Butler, Ellie; Kirkwood, Amy A; Messina, Monica; Pavoni, Chiara; Morgades, Mireia; Harrison, Christine J; Foà, Robin; Ribera, Josep-Maria; Chiaretti, Sabina; Bassan, Renato; Fielding, Adele K; Moorman, Anthony V.
Afiliación
  • Enshaei A; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Joy M; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Butler E; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Kirkwood AA; Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK.
  • Messina M; Gruppo Italiano Malattie Ematologiche dell'Adulto Foundation, Rome, Italy.
  • Pavoni C; Unit of Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Morgades M; Clinical Hematology Department, ICO-Hospital Germans Trias I Pujol, Josep Carreras Research Institute, Badalona, Spain.
  • Harrison CJ; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Foà R; Hematology Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Ribera JM; Clinical Hematology Department, ICO-Hospital Germans Trias I Pujol, Josep Carreras Research Institute, Badalona, Spain.
  • Chiaretti S; Hematology Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Bassan R; Complex Operative Unit of Hematology, dell'Angelo Hospital and Santissimi Giovanni and Paolo Hospital, Mestre and Venice, Venezia-Mestre, Italy.
  • Fielding AK; UCL Cancer Institute, London, United Kingdom.
  • Moorman AV; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Blood Adv ; 8(5): 1155-1166, 2024 Mar 12.
Article en En | MEDLINE | ID: mdl-38113467
ABSTRACT
ABSTRACT Risk stratification is crucial to the successful treatment of acute lymphoblastic leukemia (ALL). Although numerous risk factors have been identified, an optimal prognostic model for integrating variables has not been developed. We used individual patient data from 4 contemporary academic national clinical trials, UKALL14, NILG-ALL10/07, GIMEMA-LAL1913, and PETHEMA-ALL-HR2011, to generate and validate the European Working Group for Adult ALL prognostic index (EWALL-PI), which is based on white blood cell count, genetics, and end of induction minimal residual disease (MRD). Individual patient risk scores were calculated for 778 patients aged 15 to 67 years in complete remission using the validated UKALL-PI formula, applying minor modifications to reflect differences between pediatric and adult ALL. Per-trial analysis revealed that EWALL-PI correlated with relapse and death. Regression analysis revealed that each unit increase in EWALL-PI increased the risk of relapse or death by ∼30% with no evidence of heterogeneity across trials or patient subgroups. EWALL-PI-defined risk models outperformed the stratification algorithms used by each trial. Threshold analysis revealed an EWALL-PI threshold that divided patients with B cell and T cell into standard (EWALL-PI <2.50) and high (EWALL-PI ≥2.50) risk groups, respectively. Per-trial analysis showed that patients at high risk had a significantly increased relapse rate and inferior survival compared with patients with standard risk (subdistribution hazard ratio for relapse, ranged from 1.85 to 3.28; hazard ratio for death, 1.73 to 3.03). Subgroup analysis confirmed the robustness of these risk groups by sex, age, white blood cell count, and lineage. In conclusion, we validated an integrated risk model across 4 independent adult ALL clinical trials, demonstrating its utility defining clinically relevant risk groups.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Adult / Child / Humans Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Adult / Child / Humans Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos